Skip to main content
logo
Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
0.5451
-0.0123 (-2.21%)
At close: Nov 6, 2026, 4:00 PM EST
0.5473
+0.0022 (0.40%)
After-hours: Nov 6, 2026, 7:59 PM EST

Citius Pharmaceuticals Income Statement

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Selling, General & Admin
56.9429.3730.0921.9115.6611.29
Research & Development
5.939.1611.9114.8217.6612.24
Operating Expenses
62.8638.534236.7333.3223.53
Operating Income
-57.37-38.53-42-36.73-33.32-23.53
Interest Expense
-0.7-0.27----0.01
Interest & Investment Income
0.270.110.761.180.250.26
EBT Excluding Unusual Items
-57.8-38.68-41.24-35.55-33.06-23.28
Gain (Loss) on Sale of Assets
3.83-2.393.59--
Other Unusual Items
-----0.23
Pretax Income
-57.98-38.68-38.85-31.97-33.06-23.05
Income Tax Expense
0.191.060.580.580.58-
Earnings From Continuing Operations
-58.17-39.74-39.43-32.54-33.64-23.05
Minority Interest in Earnings
11.892.310.29---
Net Income
-46.27-37.43-39.14-32.54-33.64-23.05
Preferred Dividends & Other Adjustments
--1.051.15-1.45
Net Income to Common
-46.27-37.43-40.19-33.69-33.64-24.51
Net Income Growth
------
Shares Outstanding (Basic)
22117664
Shares Outstanding (Diluted)
22117664
Shares Change
154.35%64.49%11.16%3.57%34.52%177.28%
EPS (Basic)
-2.12-3.38-5.97-5.57-5.76-5.64
EPS (Diluted)
-2.12-3.38-5.97-5.57-5.76-5.64
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Free Cash Flow
-34.87-26.55-28.2-29.06-28.36-24.26
Free Cash Flow Per Share
-1.60-2.40-4.19-4.80-4.85-5.58
EBITDA
--38.52-41.99-36.73-33.31-23.53
D&A For EBITDA
-00000
EBIT
-57.37-38.53-42-36.73-33.32-23.53
SEC Filings: 10-K · 10-Q